OTCMKTS:BPMUF Basilea Pharmaceutica (BPMUF) Stock Price, News & Analysis → The Hidden Anchor Investment of the Elite Revealed (From Colonial Metals) (Ad) Free BPMUF Stock Alerts $48.15 0.00 (0.00%) (As of 05/31/2024 ET) Add Compare Share Share Today's Range$48.15▼$48.1550-Day Range$40.75▼$48.1552-Week Range$38.60▼$48.15VolumeN/AAverage Volume133 shsMarket Capitalization$570.58 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartHeadlinesShort InterestStock AnalysisChartHeadlinesShort Interest Get Basilea Pharmaceutica alerts: Email Address Ad Wealthpin ProThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has already inked deals with the Department of Energy.Click here to get all the information about it. About Basilea Pharmaceutica Stock (OTCMKTS:BPMUF)Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union. It also offers medicine drug for invasive fungal infections. In addition, the company provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as offers treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. Further, it offers Fosmanogepix, an antifungal drug for the treatment of Candidemia which in Phase II clinical trials. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland.Read More BPMUF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BPMUF Stock News HeadlinesMay 16, 2024 | finance.yahoo.comStrong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to BasileaMay 4, 2024 | seekingalpha.comBPMUF Basilea Pharmaceutica AGMay 3, 2024 | finance.yahoo.comBasilea reports presentation of new data for ceftobiprole (Zevtera®) at ESCMID Global 2024April 24, 2024 | finance.yahoo.comBasilea shareholders approve all proposals of the board of directors at the annual general meetingApril 24, 2024 | finance.yahoo.comBasilea Pharmaceutica AG (0QNA.L)April 9, 2024 | finance.yahoo.comBasilea awarded CARB-X grant to develop recently acquired novel class of antibioticsApril 4, 2024 | msn.comUPDATE 2-US FDA approves Basilea Pharmaceutica's antibioticApril 4, 2024 | msn.comEuropean stocks rise ahead of inflation data; Basilea shinesApril 4, 2024 | finance.yahoo.comBasilea announces US FDA approval of antibiotic ZEVTERA® (ceftobiprole medocaril) for three indicationsApril 3, 2024 | reuters.comUS FDA approves Basilea Pharmaceutica's antibioticMarch 11, 2024 | finance.yahoo.comContinued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to BasileaFebruary 21, 2024 | investing.comBasilea Pharmaceutica AG (BSLN)February 13, 2024 | finance.yahoo.comBasilea reports strong 2023 full-year results with profitability significantly above guidance, whilst substantially expanding the R&D portfolioJanuary 19, 2024 | finance.yahoo.comCresemba® sales in Latin America trigger first sales milestone payment to BasileaJanuary 15, 2024 | markets.businessinsider.comBasilea To Buy Preclinical Antibiotics Program From SpexisJanuary 15, 2024 | finance.yahoo.comBasilea announces acquisition of preclinical antibiotics program from SpexisJanuary 5, 2024 | finance.yahoo.comBasilea provides portfolio status updateDecember 20, 2023 | markets.businessinsider.comBasilea Pharmaceutica Agrees With Athyrium On Early Repayment Of Senior Secured LoanDecember 20, 2023 | finance.yahoo.comBasilea announces accelerated loan repaymentDecember 11, 2023 | finance.yahoo.comBasilea announces that FDA approves expanded use of antifungal Cresemba® (isavuconazole) in the United States in children with invasive aspergillosis and invasive mucormycosisDecember 4, 2023 | finance.yahoo.comBasilea Pharmaceutica AG's (VTX:BSLN) top owners are individual investors with 58% stake, while 39% is held by institutionsNovember 20, 2023 | finance.yahoo.comContinued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers third sales milestone payment for the region from Pfizer this yearNovember 13, 2023 | msn.comPfizer unit in pact with Swiss biotech Basilea to sell rights to antifungalNovember 13, 2023 | finance.yahoo.comBasilea announces acquisition of fosmanogepix, a phase-3-ready broad-spectrum antifungalOctober 31, 2023 | finance.yahoo.comBasilea announces exclusive license and option agreement for potential first-in-class clinical-stage antibacterial agentSee More Headlines Receive BPMUF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Basilea Pharmaceutica and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today6/03/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:BPMUF CUSIPN/A CIKN/A Webwww.basilea.com Phone(161) 606-1111Fax41-61-606-1112Employees147Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio3.20 Quick Ratio2.64 Sales & Book Value Annual Sales$175.50 million Price / Sales3.25 Cash Flow$1.13 per share Price / Cash Flow42.61 Book Value($0.94) per share Price / Book-51.22Miscellaneous Outstanding Shares11,850,000Free FloatN/AMarket Cap$570.58 million OptionableNot Optionable Beta0.66 Social Links 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. David Veitch (Age 59)Chief Executive Officer Comp: $1.25MMr. Adesh Kaul (Age 50)Chief Financial Officer Dr. Gerrit Hauck Ph.D. (Age 60)Chief Technology Officer Dr. Laurenz Kellenberger Ph.D. (Age 57)Chief Scientific Officer Dr. Marc Engelhardt M.D. (Age 60)Chief Medical Officer Dr. Peer Nils SchroderHead of Corporate Communications & Investor RelationsMr. Damian Heller (Age 58)General Counsel & Corporate Secretary Mr. Andreas KuminHead of Corporate DevelopmentMs. Ursula Eberhardt (Age 62)Head of Global Human Resources Mr. Mark Jones (Age 56)Head of Project Management & Preclinical Development More ExecutivesKey CompetitorsBausch Health CompaniesNYSE:BHCRhythm PharmaceuticalsNASDAQ:RYTMDeciphera PharmaceuticalsNASDAQ:DCPHAgios PharmaceuticalsNASDAQ:AGIOAmneal PharmaceuticalsNASDAQ:AMRXView All Competitors BPMUF Stock Analysis - Frequently Asked Questions How have BPMUF shares performed in 2024? Basilea Pharmaceutica's stock was trading at $41.00 at the beginning of 2024. Since then, BPMUF stock has increased by 17.4% and is now trading at $48.15. View the best growth stocks for 2024 here. Are investors shorting Basilea Pharmaceutica? Basilea Pharmaceutica saw a decrease in short interest in the month of April. As of April 30th, there was short interest totaling 85,300 shares, a decrease of 59.3% from the April 15th total of 209,600 shares. Based on an average trading volume of 0 shares, the short-interest ratio is currently ∞ days. View Basilea Pharmaceutica's Short Interest. How do I buy shares of Basilea Pharmaceutica? Shares of BPMUF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does Basilea Pharmaceutica have any subsidiaries? The following companies are subsidiares of Basilea Pharmaceutica: Conec UK Limited.Read More This page (OTCMKTS:BPMUF) was last updated on 6/3/2024 by MarketBeat.com Staff From Our PartnersThe Only Energy Play You Should Be Looking AtWealthpin Pro[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Crypto 101 MediaBiden replacement revealed?Paradigm PressNext President (Not Trump. Not Biden.)The Freeport SocietyCollapse of the Petrodollar Colonial Metals[Webinar] Understanding Covered CallsOICWhat’s Pelosi Buying Now?AltimetryAlex's "Next Magnificent Seven" StocksThe Oxford Club Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Basilea Pharmaceutica AG Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.